News | November 14, 2025
Pfizer completes up to $10 billion acquisition of Metsera
Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape
Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape
This remarkable increase from 17 in 2021 ranks among the fastest for pharmaceutical companies, establishing Lupin as a leader in sustainable growth
Dexlansoprazole delayed-release capsules are a proton pump inhibitor
Sepsis is a life-threatening reaction to infection that overwhelms the body’s defenses
The trial will evaluate safety endpoints including dose-limiting toxicities and adverse events
Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio
Cardiovascular disease (CVD) is the leading cause of death in the US and worldwide with over 82 million Americans living with CVD
Fenebrutinib targets cells in the immune system known as B cells and microglia
The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology
The data highlight sustained intraocular pressure (IOP) reduction, drop-free treatment outcomes, and strong visual performance
Subscribe To Our Newsletter & Stay Updated
